|
(11) | EP 2 454 249 B1 |
| (12) | EUROPEAN PATENT SPECIFICATION |
|
|
| (54) |
COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF VERBINDUNGEN ALS HYPOXIE-MIMETIKA, ZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON COMPOSÉS UTILES EN TANT QUE MIMÉTIQUES D'HYPOXIE, ET COMPOSITIONS, ET UTILISATIONS ASSOCIÉES |
|
|
|||||||||||||||||||||||||||||||
| Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). |
FIELD OF THE INVENTION
[0001] The present invention relates to substituted heterocyclic compounds, and compositions thereof as well as such compounds and compositions for use as hypoxia mimetics. This invention further discloses methods of increasing HIF (Hypoxia Inducible Factor) levels or activity in a subject or treating a condition associated with HIF levels or activity such as ischemia, anemia, wound healing, auto-transplantation, allo-transplantation, xenotransplantation, systemic high blood pressure, thalassemia, diabetes, cancer, and an inflammatory disorder.
BACKGROUND OF THE INVENTION
[0002] The cellular transcription factor HIF (Hypoxia Inducible Factor) occupies a central position in oxygen homeostasis in a wide range of organisms and is a key regulator of responses to hypoxia. The genes regulated by HIF transcriptional activity can play critical roles in angiogenesis, erythropoiesis, hemoglobin F production, energy metabolism, inflammation, vasomotor function, apoptosis and cellular proliferation. HIF can also play a role in cancer, in which it is commonly upregulated, and in the pathophysiological responses to ischemia and hypoxia.
[0003] The HIF transcriptional complex comprises an heterodimer: HIF is a constitutive nuclear protein that dimerizes with oxygen-regulated HIF subunits. Oxygen regulation occurs through hydroxylation of the HIF subunits, which are then rapidly destroyed by the proteasome. In oxygenated cells, the von Hippel-Lindau tumor suppressor protein (pVHL) binds to hydroxylated HIF-subunits, thereby promoting their ubiquitin dependent proteolysis. This process is suppressed under hypoxic conditions, stabilizing HIF and promoting transcriptional activation by the HIF complex.
[0004] Hydroxylation of HIF-subunits can occur on proline and asparagine residues and can be mediated by a family of 2-oxoglutarate dependent enzymes. This family includes the HIF prolyl hydroxylase isozymes (PHDs), which hydroxylate Pro 402 and Pro 564 of human HIF1, as well as Factor Inhibiting HIF (FIH), which hydroxylates Asn 803 of human HIF1. Inhibition of FIH or the PHDs leads to HIF stabilization and transcriptional activation. See, e.g., Schofield and Ratcliffe, Nature Rev. Mol. Cell Biol., Vol5, pages 343-354 (2004).
[0005] WO 2007/103905 describes bicyclic heteroaromatic N-substituted glycine derivatives, which are described to be antagonists of HIF prolyl hydroxylases and are described to be useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
[0007] Thus, new or improved agents that modulate (such as increasing HIF levels or activity) HIF are continually needed for developing new and more effective pharmaceuticals to treat HIF-associated conditions or diseases or disorders, such as ischemia, anemia, wound healing, auto-transplantation, allo-transplantation, xenotransplantation, systemic high blood pressure, thalassemia, diabetes, cancer, and an inflammatory disorder, to name a few. In discovering new or improved agents that modulate HIF level or activity, it is also desirable but not required to discover agents with improved chemical or biological properties such as solubility, bioavailability, pharmacokinetics, pharmacodynamics, toxicity and/or less side effects such as less cardiovascular side effects. The compounds, compositions, and methods described herein are directed toward these needs and other ends.
SUMMARY OF THE INVENTION
[0008] The present invention provides, inter alia, compounds of Formula I:
or a pharmaceutically acceptable salt thereof, a solvate thereof or a chelate thereof as defined in claim 1.
[0009] The present invention further provides pharmaceutical compositions as defined in claim 58. The present invention further provides use of the compounds of Formula I in the manufacture of a medicament for the treatment of a disease, disorder, or condition as defined in claim 62.
DESCRIPTION OF DRAWINGS
[0011]
Figure 1 illustrates certain example compounds' effects on the level of EPO in mice 4 hours after the administration of different compounds (using the assay described in Example B).
Figure 2 illustrates certain example compounds' effects on the level of red blood cell counts (RBC) in mice at Day 9 after 7 days of daily dosage of 60 mg/kg (using the assay described in Example C).
Figure 3 illustrates certain example compounds' effects on the level of blood hemoglobin (HGB) in mice at Day 9 after 7 days of daily dosage of 60 mg/kg (using the assay described in Example C).
Figure 4 illustrates the pharmacokinetic curves in rats for certain example compounds after single oral dosage of 50 mg/kg (using the assay described in Example D).
DETAILED DESCRIPTION
[0012] The present invention provides, inter alia, compounds of Formula I:
or a pharmaceutically acceptable salt thereof, a solvate thereof, or a chelate thereof, wherein:
n is 1 to 6;
R1 is OH, SH, NR3R4, NHC(O)R2, NHSO2R2 or sulfonyl;
R2 is H, C1-C6 alkyl or substituted C1-C6 alkyl;
R3 and R4 are each independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 haloalkyl, substituted C1-C6 haloalkyl; or at least one pair of R3 and R4, together with the same carbon atom to which they are attached, may join to form a 3 to 6 membered ring or a substituted 3 to 6 membered ring;
R5 is OH, SH, NH2, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, or sulfanyl;
each of R6 and R7 is independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, NR3R4, C(O)OH, OR12, SR12, SO2R12, CN, NO2, halo, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkylsilyl, substituted alkylsilyl, alkynylsilyl, substituted alkynylsilyl, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, or -X-R11;
or R6 and R7, together with the carbon atoms to which they are attached, join to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring;
X is -N(R10)-Y- or -Y-N(R10)-;
Y is C(O), SO2, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, or substituted alkynylene;
R8 is H, heteroaryl, substituted heteroaryl, phenyl, or phenyl substituted by halogen, alkyl, alkoxy, haloalkyl, or haloalkoxy, wherein at least one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the para- or meta- position; or wherein one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the para- or meta- position; and the other of R8 and R9 is H, halogen, OH, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy; or wherein one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the para- or meta- position; and the other of R8 and R9 is H;
R10 is H, C1-C6 alkyl, or substituted C1-C6 alkyl;
R11 is H, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; and
R12 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or NR3R4;
wherein substituted refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s) wherein substituents include -X, -R33, -OH, =O, -OR33, SR33, -SH, =S, -NR33R34, =NR33, -CX3, -CF3, -CN, -NO2, -S(O)2R33, -OS(O2)OH, -OS(O)2R33, -OP(O)(OR33)(OR34), -C(O)R33, -C(S)R33, -C(O)OR33, -C(O)NR33R34, -C(O)OH, -C(S)OR33, -NR35C(O)NR33R34, -NR35C(S)NR33R34, -NR35C(NR33)NR33R34, -C(NR33)NR33R34, -S(O)2NR33R34, -NR35S(O)2R33, -NR35C(O)R33, and S(O)R33 where each X is independently a halo; each R33 and R34 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl , substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, -NR35R36, -C(O)R35 or -S(O)2R35 or optionally R33 and R34 together with the atom to which R33 and R34 are attached form one or more heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl rings; and R35 and R36 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, or optionally R35 and R36 together with the nitrogen atom to which R35 and R36 are attached form one or more heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl rings.
[0018] In some embodiments, R3 and R4 are each independently H or C1-C6 alkyl (such as methyl or ethyl).
[0022] In some embodiments, at least one of R6 and R7 is halo or a moiety substituted with at least one halo.
[0023] In some embodiments, at least one of R6 and R7 is independently alkoxy or substituted alkoxy..
[0024] In some embodiments, at least one of R6 and R7 is independently aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl.
[0027] In some embodiments, one of R8 and R9 is phenyl or phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, or haloalkoxy at the para- and/or meta- position.
[0028] In some embodiments, R8 is pyridyl or pyridyl substituted with halogen, alkyl, haloalkyl, alkoxy, or haloalkoxy at the para- and/or meta- position.
[0029] In some embodiments, the compound of Formula I is a compound of Formula II:
wherein:
R21 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;
R22 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;
Z1 is CR23; and R23 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;
provided that at least one of R21 and R22 and R23, if present, is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0030] In some embodiments of compound of Formula II, R21 is H, Cl, F, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or trifluoromethoxy.
[0031] In some embodiments of compound of Formula II, R22 is H, Cl, F, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or trifluoromethoxy.
[0032] In some embodiments of compound of Formula II, R23 is H, Cl, F, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or trifluoromethoxy.
[0033] In some embodiments of compound of Formula II, one of R21, R22, and R23 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and the other two of R21, R22, and R23 are each H.
[0034] In some embodiments of compound of Formula II, one of R21 and R23 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and the other one of R21 and R23 is H.
[0036] In some embodiments of compound of Formula II, two of R21, R22, and R23 are each independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and the other one of R21, R22, and R23 is H.
[0038] In some embodiments of compound of Formula II, R21, R22, and R23 are each independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0039] In some embodiments of compound of Formula II one of R21 and R22 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and the other of R21 and R22 is H.
[0040] In some embodiments, the compound of Formula II is a compound of Formula IIa:
wherein:
R21 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and
R22 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;
provided that at least one of R21 and R22 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0041] In some embodiments of compound of Formula IIa, R21 is H; and R22 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0042] In some embodiments of compound of Formula IIa, R21 is H; and R22 is C1-C6 alkyl or C1-C6 haloalkyl.
[0045] In some embodiments of compound of Formula IIa, R22 is H; and R21 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0046] In some embodiments of compound of Formula IIa, R22 is H; and R21 is C1-C6 alkyl or C1-C6 haloalkyl.
[0049] In some embodiments of compound of Formula IIa, R21 and R22 are each independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0050] In some embodiments of compound of Formula IIa, R21 and R22 are each independently C1-C2 alkyl or C1-C2 haloalkyl.
[0051] In some embodiments, the compound of Formula I is a compound of Formula III:
wherein:
R24 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;
R25 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6r haloalkoxy;
Z2 is N or CR26; and R26 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;
provided that at least one of R24 and R25 and R26 , if present, is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0053] In some embodiments of compound of Formula III, R24 is H, Cl, F, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or trifluoromethoxy.
[0054] In some embodiments of compound of Formula III, R25 is H, Cl, F, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or trifluoromethoxy.
[0055] In some embodiments of compound of Formula III, Z2 is CR26 and R26 is H, Cl, F, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or trifluoromethoxy.
[0056] In some embodiments of compound of Formula III, Z2 is CR26; one of R24, R25, and R26 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and the other two of R24, R25, and R26 are each H.
[0057] In some embodiments of compound of Formula III, Z2 is CR26; one of R24 and R26 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and the other one of R24 and R26 is H.
[0058] In some embodiments of compound of Formula III, Z2 is CR26; two of R24, R25, and R26 are each independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and the other one of R24, R25, and R26 is H.
[0059] In some embodiments of compound of Formula III, Z2 is CR26; R24, R25, and R26 are each independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0061] In some embodiments of compound of Formula III, one of R24 and R25 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy,or C1-C6 haloalkoxy; and the other of R24 and R25 is H.
[0062] In some embodiments, the compound of Formula III is a compound of Formula IIIa
wherein:
R24 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy; and
R25 is H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy;
provided that at least one of R24 and R25 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0063] In some embodiments of compound of Formula IIIa, R24 is H; and R25 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0065] In some embodiments of compound of Formula IIIa, R25 is H; and R24 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0067] In some embodiments of compound of Formula IIIa, R24 and R25 are each independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy.
[0068] In some embodiments of compound of Formula I, wherein the compound is:
2-(4-hydroxy-2-oxo-7-phenyl-2H-chromene-3-carboxamido)acetic acid;
2-(7-(2-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(7-(3-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(7-(4-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(3-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(4-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(3-(trifluoromethoxy)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(4-(trifluoromethoxy)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(7-(3,4-dichlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(7-(3,4-difluorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(3,4,5-trifluorophenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-7-(3-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-7-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-m-tolyl-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-p-tolyl-2H-chromene-3-carboxamido)acetic acid;
2-(8-(2-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(8-(3-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(8-(4-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(3-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(4-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(3-(trifluoromethoxy)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(4-(trifluoromethoxy)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(8-(3,4-dichlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(8-(3,4-difluorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(3,4,5-trifluorophenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-8-(3-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-8-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-m-tolyl-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-p-tolyl-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-7-(6-methoxypyridin-3-yl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(pyridin-4-yl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(pyridin-3-yl)-2H-chromene-3-carboxamido)acetic acid; or
2-(4-hydroxy-2-oxo-8-(3-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid.
[0069] Also provided herein is a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient, adjuvant, or carrier, and a therapeutically effective amount of at least one compound described herein.
[0070] Further provided are pharmaceutical compositions comprising at least one pharmaceutically acceptable excipient, adjuvant, or carrier, and a therapeutically effective amount of at least one compound described herein.
[0071] In some embodiments, the pharmaceutical compositions comprise at least one additional compound such as an erythropoiesis stimulating agent or chemotherapeutic agent.
[0072] Additionally provided herein is the pharmaceutical compositions with at least one compound described herein or pharmaceutically acceptable salt thereof in an amount effective for the treatment of ischemia, anemia, wound healing, auto-transplantation, allo-transplantation, xeno-transplantation, systemic high blood pressure, thalassemia, diabetes, cancer, an inflammatory disorder, or a combination thereof.
[0073] Further provided is the pharmaceutical compositions with at least one compound described herein or pharmaceutically acceptable salt thereof in an amount effective for the treatment of a disease, a disorder, a condition associated with the HIF level or HIF activity.
[0074] Also provided is a use of a compound described herein or pharmaceutically acceptable salt thereof in the manufacturing a medicament for, treating an anemic or ischemic related disorder in a subject comprising administering to a subject at least one compound described herein.
[0075] Also provided is a use of a compound described herein or pharmaceutically acceptable salt thereof in the manufacturing a medicament for, treating ischemia, anemia, wound healing, auto-transplantation, allo-transplantation, xeno-transplantation, systemic high blood pressure, thalassemia, diabetes, cancer, an inflammatory disorder, or a combination of two or more thereof in a subject comprising administering to a subject at least one compound described herein.
[0076] Also provided is a use of a compound described herein or pharmaceutically acceptable salt thereof in the manufacturing a medicament for, treating anemia in a subject comprising administering to a subject at least one compound described herein.
[0077] Also provided is a use of a compound described herein or pharmaceutically acceptable salt thereof in the manufacturing a medicament for, modulating angiogenesis in a subject comprising administering to the subject at least one compound described herein.
[0078] Additionally provided is a use of a compound described herein or pharmaceutically acceptable salt thereof in the manufacturing a medicament for, treating at least one disease in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound described herein.
[0079] Also provided is a use of a compound described herein or pharmaceutically acceptable salt thereof in the manufacturing a medicament for, inhibiting HIF hydroxylation in a subject comprising administering to the subject at least one compound described herein.
[0080] Additional embodiments of the invention are set forth in the description which follows, or may be learned by practice of the invention.
[0081] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the standard deviation found in their respective testing measurements.
[0082] As used herein, when any variable occurs more than one time in a chemical formula, its definition on each occurrence is independent of its definition at every other occurrence. The compounds of the present disclosure may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers or diastereomers. Accordingly, any chemical structures within the scope of the specification depicted, in whole or in part, with a relative configuration encompass all possible enantiomers and stereoisomers of the illustrated compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into the component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan.
[0083] Compounds of Formula I, II, IIa, III and IIIa include, but are not limited to optical isomers of compounds of Formula I, II, IIa, III and IIIa, racemates, and other mixtures thereof. In those situations, the single enantiomers or diastereomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high-pressure liquid chromatography (HPLC) column. In addition, compounds of Formula I, II, IIa, III and IIIa include Z- and E- forms (or cis- and trans- forms) of compounds with double bonds. Where compounds of Formula I, II, IIa, III and IIIa exists in various tautomeric forms, chemical entities of the present invention include all tautomeric forms of the compound.
[0084] Compounds of the present disclosure include, but are not limited to compounds of Fomula I and all pharmaceutically acceptable forms thereof. Pharmaceutically acceptable forms of the compounds recited herein include pharmaceutically acceptable salts, solvates, crystal forms (including polymorphs and clathrates), chelates, non-covalent complexes, prodrugs, and mixtures thereof. In certain embodiments, the compounds described herein are in the form of pharmaceutically acceptable salts. As used henceforth, the term "compound" encompasses not only the compound itself, but also a pharmaceutically acceptable salt thereof, a solvate thereof, a chelate thereof, and mixtures of any of the foregoing.
[0085] The term "solvate" refers to the compound formed by the interaction of a solvent and a compound. Suitable solvates are pharmaceutically acceptable solvates, such as hydrates, including monohydrates and hemi-hydrates.
[0086] At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term "C1-3 alkyl" is specifically intended to individually disclosed methyl, ethyl, and C3 alkyl (including n-propryl and isopropyl).
[0087] For compounds of the invention in which a variable appears more than once, each variable can be a different moiety selected from the Markush group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound; the two R groups can represent different moieties selected from the Markush group defined for R.
[0088] It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
[0089] The term "n-membered" where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, pyridine is an example of a 6-membered heteroaryl ring and thiophene is an example of a 5-membered heteroaryl group.
[0090] "Alkyl" refers to a saturated, branched or straight-chain monovalent hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyls such as propan-1-yl, propan-2-yl, and cyclopropan-1-yl, butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, tert-butyl, and the like. In certain embodiments, an alkyl group comprises from 1 to 20 carbon atoms. As used herein the term "lower alkyl" refers to an alkyl group comprising from 1 to 6 carbon atoms.
[0091] "Alkenyl" refers to an unsaturated branched, straight-chain or cyclic alkyl group having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene. The group may be in either the Z- or E- forms (or cis or trans conformation) about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl; cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta- 1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl;and the like. In certain embodiments, an alkenyl group has from 2 to 20 carbon atoms and in other embodiments, from 2 to 6 carbon atoms, i.e. "lower alkenyl."
[0092] "Alkynyl" refers to an unsaturated branched or straight-chain having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne. Typical alkynyl groups include, but are not limited to, ethynyl; propynyl; butynyl, 2-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl and the like. In certain embodiments, an alkynyl group has from 2 to 20 carbon atoms and in other embodiments, from 2 to 6 carbon atoms (i.e. "lower alkynyl").
[0093] "Alkoxy" refers to a radical -OR where R represents an alkyl. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclohexyloxy, and the like.
[0095] "Aryl" refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Aryl encompasses 5- and 6-membered carbocyclic aromatic rings, for example, benzene; bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, naphthalene, indane, and tetralin; and tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene. For example, aryl includes 5- and 6-membered carbocyclic aromatic rings fused to a 5- to 7-membered heterocycloalkyl ring containing 1 or more heteroatoms selected from N, O, and S. In certain embodiments, an aryl group can comprise from 6 to 10 carbon atoms. Aryl, however, does not encompass or overlap in any way with heteroaryl, separately defined below. Hence, if one or more carbocyclic aromatic rings is fused with a heterocycloalkyl aromatic ring, the resulting ring system is heteroaryl, not aryl, as defined herein.
[0096] "Arylalkyl" or "aralkyl" refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkyl, arylalkenyl, and/or arylalkynyl is used. In certain embodiments, an arylalkyl group can be (C6-30) arylalkyl, e.g., the alkyl group of the arylalkyl group can be (C1-10) and the aryl moiety can be (C5-20).
[0100] "Cycloalkyl" refers to a saturated or unsaturated, but non-aromatic, cyclic alkyl group. Where a specific level of saturation is intended, the nomenclature "cycloalkanyl" or "cycloalkenyl" is used. Typical cycloalkyl groups include, but are not limited to, groups derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane, and the like. In certain embodiments, the cycloalkyl group can be C3-10 cycloalkyl, such as, for example, C3-6 cycloalkyl.
[0101] "Heterocycloalkyl" refers to a saturated or unsaturated, but non-aromatic, cyclic alkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom and its associated hydrogen atoms, where appropriate. Typical heteroatoms to replace the carbon atom(s) include, but are not limited to, N, P, O, S, and Si. Where a specific level of saturation is intended, the nomenclature "heterocycloalkanyl" or "heterocycloalkenyl" is used. Typical heterocycloalkyl groups include, but are not limited to, groups derived from epoxides, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran and the like. Substituted heterocycloalkyl also includes ring systems substituted with one or more oxo (=O) or oxide (-O-) substituents, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl and 1,1-dioxo-1-thiomorpholinyl.
[0104] "Heteroaryl" refers to a monovalent heteroaromatic group derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system. Heteroaryl encompasses: 5- to 7-membered aromatic, monocyclic rings containing one or more, for example, from 1 to 4, or in certain embodiments, from 1 to 3, heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon; and polycyclic heterocycloalkyl rings containing one or more, for example, from 1 to 4, or in certain embodiments, from 1 to 3, heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring.
[0105] For example, heteroaryl includes a 5- to 7-membered heteroaromatic ring fused to a 5- to 7-membered cycloalkyl ring and a 5- to 7-membered heteroaromatic ring fused to a 5- to 7-membered heterocycloalkyl ring. For such fused, bicyclic heteroaryl ring systems wherein only one of the rings contains one or more heteroatoms, the point of attachment may be at the heteroaromatic ring or the cycloalkyl ring. When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In certain embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In certain embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1. Heteroaryl does not encompass or overlap with aryl as defined above. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arsindole, carbazole, β-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole,. indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perirnidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. In certain embodiments, the heteroaryl group can be between 5 to 20 membered heteroaryl, such as, for example, a 5 to 10 membered heteroaryl. In certain embodiments, heteroaryl groups can be those derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole, and pyrazine.
[0106] "Heteroarylalkyl" or "heteroaralkyl" refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylalkenyl, and/or heteroarylalkynyl is used. In certain embodiments, the heteroarylalkyl group can be a 6 to 30 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl can be 1 to 10 membered and the heteroaryl moiety can be a 5 to 20-membered heteroaryl.
[0107] "Sulfonyl" refers to a radical -S(O)2R where R is an alkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl group as defined herein. Representative examples include, but are not limited to methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, and the like.
[0108] "Sulfanyl" refers to a radical -SR where R is an alkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl group as defined herein that may be optionally substituted as defined herein. Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, and the like.
[0109] "Pharmaceutically acceptable" refers to generally recognized for use in animals, and more particularly in humans.
[0110] "Pharmaceutically acceptable salt" refers to a salt of a compound that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, dicyclohexylamine, and the like.
[0111] "Pharmaceutically acceptable excipient," "pharmaceutically acceptable carrier," or "pharmaceutically acceptable adjuvant" refer, respectively, to an excipient, carrier or adjuvant with which at least one compound of the present disclosure is administered.
[0112] "Pharmaceutically acceptable vehicle" refers to any of a diluent, adjuvant, excipient or carrier with which at least one compound of the present disclosure is administered.
[0113] "Stereoisomer" refers to an isomer that differs in the arrangement of the constituent atoms in space. Stereoisomers that are mirror images of each other and optically active are termed "enantiomers," and stereoisomers that are not mirror images of one another and are optically active are termed "diastereoisomers."
[0114] "Subject" includes mammals and humans. The terms "human" and "subject" are used interchangeably herein.
[0115] "Substituted" refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s). Typical substituents include, but are not limited to, -X, -R33, -OH, =O, -OR33, SR33, -SH, =S, -NR33R34, =NR33, -CX3, -CF3, -CN, -NO2, -S(O)2R33, -OS(O2)OH, -OS(O)2R33, -OP(O)(OR33)(OR34), -C(O)R33, -C(S)R33, -C(O)OR33, -C(O)NR33R34, -C(O)OH, -C(S)OR33, -NR35C(O)NR33R34, -NR35C(S)NR33R34, -NR35C(NR33)NR33R34, -C(NR33)NR33R34, -S(O)2NR33R34, -NR35S(O)2R33, -NR35C(O)R33, and S(O)R33 where each X is independently a halo; each R33 and R34 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, -NR35R36, -C(O)R35 or -S(O)2R35 or optionally R33 and R34 together with the atom to which R33 and R34 are attached form one or more heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl rings; and R35 and R36 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, or optionally R35 and R36 together with the nitrogen atom to which R35 and R36 are attached form one or more heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl rings. In certain embodiments, a tertiary amine or aromatic nitrogen may be substituted with one or more oxygen atoms to form the corresponding nitrogen oxide.
[0116] "Therapeutically effective amount" refers to the amount of a compound that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or symptom. The "therapeutically effective amount" can vary depending on the compound, the disease, disorder, and/or symptoms of the disease or disorder, severity of the disease, disorder, and/or symptoms of the disease or disorder, the age of the subject to be treated, and/or the weight of the subject to be treated. An appropriate amount in any given instance can be readily apparent to those skilled in the art or capable of determination by routine experimentation.
[0117] "Treating" or "treatment" of any disease or disorder refers to arresting or ameliorating a disease, disorder, or at least one of the clinical symptoms of a disease or disorder, reducing the risk of acquiring a disease, disorder, or at least one of the clinical symptoms of a disease or disorder, reducing the development of a disease, disorder or at least one of the clinical symptoms of the disease or disorder, or reducing the risk of developing a disease or disorder or at least one of the clinical symptoms of a disease or disorder. "Treating" or "treatment" also refers to inhibiting the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both, or inhibiting at least one physical parameter which may not be discernible to the subject. Further, "treating" or "treatment" refers to delaying the onset of the disease or disorder or at least symptoms thereof in a subject which may be exposed to or predisposed to a disease or disorder even though that subject does not yet experience or display symptoms of the disease or disorder.
[0118] Reference will now be made in detail to embodiments of the present disclosure. While certain embodiments of the present disclosure will be described, it will be understood that it is not intended to limit the embodiments of the present disclosure to those described embodiments. To the contrary, reference to embodiments of the present disclosure is intended to cover alternatives, modifications, and equivalents as may be included within the spirit and scope of the embodiments of the present disclosure as defined by the appended claims.
[0119] Certain embodiments of the present invention are directed to at least one compound of Formula I:
Or a pharmaceutically acceptable salt thereof, a solvate thereof, or a chelate thereof, wherein:
n is 1 to 6;
R1 is OH, SH, NR3R4, NHC(O)R2, NHSO2R2 or sulfonyl,;
R2 is H, C1-C6 alkyl or substituted C1-C6 alkyl;
R3 and R4 are each independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 haloalkyl, substituted C1-C6 haloalkyl; or at least one pair of R3 and R4, together with the same carbon atom to which they are attached, may join to form a 3 to 6 membered ring or a substituted 3 to 6 membered ring;
R5 is OH, SH, NH2, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, or sulfanyl;
each of R6 and R7 is independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, NR3R4, C(O)OH, OR12, SR12, SO2R12, CN, NO2, halo, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkylsilyl, substituted alkylsilyl, alkynylsilyl, substituted alkynylsilyl, alkoxy, substituted alkoxy,alkoxycarbonyl, substituted alkoxycarbonyl, or -X-R11;
or R6 and R7 together with the carbon atoms to which they are attached join to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring;
X is -N(R10)-Y- or -Y-N(R10)-;
Y is C(O), SO2, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, or substituted alkynylene;
R8 is H, heteroaryl, substituted heteroaryl, phenyl, or phenyl substituted by halogen, alkyl, alkoxy, haloalkyl, or haloalkoxy, wherein at least one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the para- or meta- position; or wherein one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the para- or meta- position; and the other of R8 and R9 is H, halogen, OH, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy; or wherein one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the para- or meta- position; and the other of R8 and R9 is H;
R10 is H, C1-C6 alkyl, or substituted C1-C6 alkyl;
R11 is H, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; and
R12 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or NR3R4; wherein substituted refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s) wherein substituents include -X, -R33, -OH, =O, -OR33, SR33, -SH, =S, -NR33R34, =NR33, -CX3, -CF3, -CN, -NO2, -S(O)2R33, -OS(O2)OH, -OS(O)2R33, -OP(O)(OR33)(OR34), -C(O)R33, -C(S)R33, -C(O)OR33, -C(O)NR33R34, -C(O)OH, -C(S)OR33, -NR35C(O)NR33R34, -NR35C(S)NR33R34, -NR35C(NR33)NR33R34, -C(NR33)NR33R34, -S(O)2NR33R34, -NR35S(O)2R33, -NR35C(O)R33, and S(O)R33 where each X is independently a halo; each R33 and R34 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, -NR35R36, -C(O)R35 or -S(O)2R35 or optionally R33 and R34 together with the atom to which R33 and R34 are attached form one or more heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl rings; and R35 and R36 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, or optionally R35 and R36 together with the nitrogen atom to which R35 and R36 are attached form one or more heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl rings.
[0122] In certain embodiments of compounds of Formula I, R3 and R4 are each independently H, C1-C6 alkyl such as methyl or ethyl, and substituted C1-C6 alkyl (such as C1-C6 alkyl substituted with hydroxyl, for example hydroxymethyl).
[0124] In certain embodiments of compounds of Formula I, R5 is OH, SH, NH2, or C1-C6 alkoxy, such as methoxy, ethoxy and propoxy, and a substituted C1-C6 alkoxy.
[0125] In certain embodiments of compounds of Formula I, R3 and R4 join together to form a 3 to 6 membered ring or a substituted 3 to 6 membered ring. The 3 to 6 membered rings can comprise at least one heteroatom, such as at least two heteroatoms.
[0126] In certain embodiments of compounds of Formula I, R6 and R7 can join together to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring. The 4 to 7 membered rings can comprise at least one heteroatom, such as at least two heteroatoms, and at least three heteroatoms.
[0127] In certain embodiments of compounds of Formula I, at least one of R6 and R7 is independently halo and a moiety substituted with at least one halogen, such as trifluoromethyl.
[0128] In certain embodiments of compounds of Formula I, at least one of R6 and R7 is independently alkoxy or substituted alkoxy.
[0129] In certain embodiments of compounds of Formula I, at least one of R6 and R7 is independently aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl, such as substituted pyridines, substituted pyrimidines, substituted pyrazines, substituted pyridazines, substituted tetrahydrofurans, and substituted piperidines.
[0130] Examples of individual representative compounds of the present disclosure, and compounds comprised in compositions of the present disclosure, and used in methods of the present disclosure are listed in Table 1. Each compound listed in Table 1, i.e., Examples 1-38, contains information directed to its structure, name, molecular weight, hydrogen NMR data and at least one method of synthesis.
[0131] In certain embodiments, compounds of the present disclosure inhibit prolyl hydroxylases such as HIF prolyl hydroxylases. Variety of assays may be used to determine the prolyl hydroxylase inhibitory activity of a compound.
[0132] In certain embodiments, compounds of the present disclosure modulate HIF levels or activity, for example, by stabilizing HIF.
[0133] Furthermore, compounds of the present disclosure can contain one or more chiral centers. Such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers, and enriched mixtures thereof, are included within the scope of the present disclosure. Pure stereoisomers, and enriched mixtures thereof, can be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.
[0134] Certain embodiments of the present disclosure are directed to a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient, adjuvant or carrier, and a therapeutically effective amount of at least one compound described herein. The at least one compound can be present in an amount effective for the treatment of at least one disease selected from ischemia, anemia, wound healing, auto-transplantation, allo-transplantation, xeno-transplantation, systemic high blood pressure, thalassemia, diabetes, cancer and an inflammatory disorder.
Synthesis
[0135] Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
[0136] The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
[0137] Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.
[0138] Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
[0139] The compounds of invention can be prepared, for example, according to one or more of the following general reaction schemes and techniques described below.
Examples
[0140] The present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds of Formulas I, II, IIa, III, or IIIa, according to the invention.
Example 1
Synthesis of N-[(4-hydroxy-2-oxo-7-phenyl-2H-3-chromenyl)carbonyl]glycine
[0142] Reagent 1 (42 g, 33.6 mmol) was dissolved in 200 mL of AC2O with addition of 1 mL of H3PO4, and was heated at 50°C. After its completion, the reaction mixture was cooled to room temperature, and 500 mL of water was then added in and stirred at 50°C until hydrolyzation is complete. The reaction mixture was then cooled to 0 °C and filtered. The resulting solid, Compound 2, was further dried (47 g).
[0143] Compound 2 (25.9 g, 100 mmol) and 1-Hydroxybenzotriazole anhydrous (HOBt, 13.5 g) was dissolved in 400 mL of THF. Dicyclohexylcarbodiimide (DCC, 20.9 g) was gradually added in at 0 °C and stirred over night at a temperature below 10°C. The reaction mixture was filtered and the Filtrate A was collected. 13.2 g (100 mmol) of dimethyl malonate was dissolved in 800 mL of THF first, then 7.2 g sodium hydride (70% dispersion) was added in. Filtrate A was added while stirred and left to react for 2 hours at room temperature. After THF removed by vacuum distillation, 400 mL of methanol and 400 mL of 10% HCl were added and stirred over night. After filtration, the resulting solid was washed with 400 mL of methanol and dried, yielding 14 g of Compound 3.
[0144] Glycine t-butyl ester HCl salt (13.4 g) and sodium methoxide (4.4 g) were suspended in 200mL of methanol. After stirred to a homogeneous suspension, it was distilled to remove all methanol. 200 mL of THF and Compound 3 (6.0 g) were added in and the reaction was run at 60°C over night. THF was then removed by vacuum distillation and 400 mL of methanol was added and stirred for 2 hours. After filtration and drying, it gave 4.5 g of Compound 4.
[0145] Compound 4 (240 mg, 0.6 mmol), Pd(PPh3)4 (140 mg, 0.12 mmol) and phenyl boronic acid (85.4 mg, 0.7 mmol) were dissolved in 1 mL of 2M Na2CO3 aqueous solution and 4 mL of DMF. The resulting solution was heated to 80°C under nitrogen gas overnight. After its completion, the reaction mixture was cooled to room temperature. 100L of water and 100mL of ethyl acetate were added and stirred. The organic layer was retained and washed twice more by water, followed by quickly passing through a silicon gel column to remove solvent. 5mL of dichloromethane and 5mL of trifluoroacetic acid were then added and stirred at room temperature for 4 hrs. After its completion, the reaction mixture was evaporated in vacuo. The resulting product was further purified by recrystallization using CH3OH-THF to arrive at the title compound 6, with the LC-MS [M-H]- m/z 338, and 1H-NMR (300 MHz, (CD3)2SO) δ 13.01 (br s, 1H), 9.55 (br s, 1H), 8.05 (d, 1H, J = 9.0 Hz), 7.85 (d, 1H, J = 9.0 Hz), 7.83 (t, 1H, J =7.5 Hz), 7.82 (dd, 2H, J = 7.5, 7.5 Hz), 7.54 (dd, 2H, J = 7.5, 1.5 Hz), 7.46 (s, 1H), 4.14 (d, 2H, J = 6.0 Hz).
Example 2
Synthesis of N-[(4-hydroxy-2-oxo-7-(2-chloro-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0147] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 373, and 1H-NMR (300 MHz, (CD3)2SO) δ 13.05 (br s, 1H), 9.57 (br s, 1H), 8.08 (d, 1H, J = 8.4 Hz), 7.66-7.32 (m, 6H), 4.15 (d, 2H, J = 6.0 Hz).
Example 3
Synthesis of N-[(4-hydroxy-2-oxo-7-(3-chloro-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0149] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 373, and 1H-NMR (300 MHz, (CD3)2SO)δ 13.05 (br s, 1H), 9.55 (br s, 1H), 8.04 (d, 1H, J = 8.4 Hz), 7.92-7.81 (m, 4H), 7.59-7.55 (m, 2H), 4.14 (d, 2H, J = 6.0 Hz).
Example 4
Synthesis of N-[(4-hydroxy-2-oxo-7-(4-chloro-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0151] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 373, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.55 (br s, 1H), 8.05 (d, 1H, J = 8.4 Hz), 7.88 (d, 2H, J = 8.7 Hz), 7.84-7.79 (m, 2H), 7.60 (d, 2H, J = 8.7 Hz), 4.14 (d, 2H, J = 6.0 Hz).
Example 5
[0152] Synthesis of N-[(4-hydroxy-2-oxo-7-(3-trifluoromethyl-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0153] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 406, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.58 (br s, 1H), 8.18 (s, 1H), 8.16 (s, 1H), 8.09 (d, 1H, J = 8.4 Hz), 7.97-7.76 (m, 4H), 4.15 (d, 2H, J = 6.0 Hz).
Example 6
Synthesis of N-[(4-hydroxy-2-oxo-7-(4-trifluoromethyl-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0155] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 406, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.56 (br s, 1H), 8.11-8.05 (m, 3H), 7.91-7.84 (m, 4H), 4.15 (d, 2H, J = 6.0 Hz).
Example 7
Synthesis of N-[(4-hydroxy-2-oxo-7-(3-trifluoromethoxy-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0157] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 422, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.57 (br s, 1H), 8.08 (d, 1H, J = 8.1 Hz), 7.92-7.85 (m, 4H), 7.69 (t, 1H), 7.50 (d, 1H, J = 8.4 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 8
Synthesis of N-[(4-hydroxy-2-oxo-7-(4-trifluoromethoxy-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0159] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 422, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.56 (br s, 1H), 8.09-7.81 (m, 5H), 7.54 (d, 2H, J = 8.4 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 9
Synthesis of N-[(4-hydroxy-2-oxo-7-(3,4-dichloro-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0161] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 407, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.57 (br s, 1H), 8.15 (s, 1H), 8.05 (d, 1H, J = 8.1 Hz), 7.92-7.78 (m, 4H), 4.15 (d, 2H, J = 6.0 Hz).
Example 10
Synthesis of N-[(4-hydroxy-2-oxo-7-(3,4-difluoro-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0163] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 374, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.55 (br s, 1H), 8.07-7.98 (m, 2H), 7.88-7.82 (m, 2H), 7.66-7.59 (m, 2H), 4.14 (d, 2H, J = 6.0 Hz).
Example 11
Synthesis of N-[(4-hydroxy-2-oxo-7-(3,4,5-trifluoro-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0165] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 392, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.55 (br s, 1H), 8.05 (d, 1H, J = 8.4 Hz), 7.97-7.85 (m, 4H), 4.14 (d, 2H, J = 6.0 Hz).
Example 12
Synthesis of N-[(4-hydroxy-2-oxo-7-(3-methoxy-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0167] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 368, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.55 (br s, 1H), 8.05 (d, 1H, J = 8.1 Hz), 7.86 (s, 1H), 7.83 (d, 1H, J = 8.1 Hz), 7.49-7.38 (m, 3H), 7.06 (d, 1H, J = 8.4 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 13
Synthesis of N-[(4-hydroxy-2-oxo-7-(4-methoxy-phenyl)-2H-3-chromenyl)carbonyl]glycine
[0169] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 368, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.56 (br s, 1H), 8.02 (d, 1H, J = 8.7 Hz), 7.85-7.78 (m, 4H), 7.09 (d, 2H, J = 9.0 Hz), 4.14 (d, 2H, J = 6.0 Hz).
Example 14
Synthesis of N-[(4-hydroxy-2-oxo-7-(3-methylphenyl)-2H-3-chromenyl)carbonyl]glycine
[0171] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 352, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.55 (br s, 1H), 8.04 (d, 1H, J = 8.7 Hz), 7.80-7.78 (m, 2H), 7.67-7.61 (m, 2H), 7.42 (t, 1H, 7.8 Hz), 7.30 (d, 1H, J = 7.5 Hz), 4.14 (d, 2H, J = 6.0 Hz), 2.50 (t, 3H, 1.8 Hz).
Example 15
Synthesis of N-[(4-hydroxy-2-oxo-7-(4-methylphenyl)-2H-3-chromenyl)carbonyl]glycine
[0173] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 352, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.56 (br s, 1H), 8.02 (d, 1H, J = 8.7 Hz), 7.79-7.73 (m, 4H), 7.34 (d, 2H, J = 8.4 Hz), 4.13 (d, 2H, J = 6.0 Hz), 2.50 (t, 3H, 1.8 Hz).
Example 16
Synthesis of N-[(4-hydroxy-2-oxo-8-phenyl-2H-3-chromenyl)carbonyl]glycine
[0175] Similar to the synthetic procedure of Example 1, Reagent 7 (27 g) was dissolved in 130 mL of AC2O with addition of 1mL of H3PO4, and was heated at 50°C. After its completion, the reaction mixture was cooled to room temperature, and 500 mL of water was then added in and stirred at 50°C until hydrolyzation is complete. The reaction mixture was then cooled to 0°C and filtered. The resulting solid, Compound 8, was further dried (24.4 g).
[0176] Compound 8 (13 g) and 1-Hydroxybenzotriazole anhydrous (HOBt, 6.8 g) was dissolved in 200 mL of THF. Dicyclohexylcarbodiimide (DCC, 10.4 g) was gradually added in at 0°C and stirred over night at a temperature below 10°C. The reaction mixture was filtered and the Filtrate B was collected. 6.6 g (50 mmol)of dimethyl malonate was dissolved in 400 mL of THF first, then 3.8 g sodium hydride (70% dispersion) was added in. Filtrate B was added while stirred and left to react for 2 hours at room temperature. After THF removed by vacuum distillation, 200 mL of methanol and 200 mL of 10% HCl were added and stirred over night. After filtration, the resulting solid was washed with 200 mL of methanol and dried, yielding 6 g of Compound 9.
[0177] Glycine t-butyl ester HCl salt (13.5 g) and sodium methoxide (4.4 g) were suspended in 200 mL of methanol. After stirred to a homogeneous suspension, it was distilled to remove all methanol. 200 mL of THF and Compound 9 (6.0 g) were added in and the reaction was run at 60°C over night. THF was then removed by vacuum distillation and 400 mL of methanol was added and stirred for 2 hours. After filtration and drying, it gave 3.5 g of Compound 10.
[0178] Compound 10 (240 mg, 0.6 mmol), Pd(PPh3)4 (140 mg, 0.12 mmol) and phenyl boronic acid (85.4 mg, 0.7 mmol) were dissolved in 1 mL of 2M Na2CO3 aqueous solution and 4 mL of DMF. The resulting solution was heated to 80°C under nitrogen gas overnight. After its completion, the reaction mixture was cooled to room temperature. 100mL of water and 100 mL of ethyl acetate were added and stirred. The organic layer was retained and washed twice more by water, followed by quickly passing through a silicon gel column to remove solvent. 5 mL of dichloromethane and 5 mL of trifluoroacetic acid were then added and stirred at room temperature for 4 hrs. After its completion, the reaction mixture was evaporated in vacuo. The resulting product was further purified by recrystallization using CH3OH-THF to arrive at the title compound 12, with the LC-MS [M-H]- m/z 338, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.51 (br s, 1H), 8.03 (dd, 1H, J = 8.1, 1.5 Hz), 7.86 (dd, 2H, J = 7.5, 1.5 Hz), 7.65-7.45 (m, 6H), 4.15 (d, 2H, J = 6.0 Hz).
Example 17
Synthesis of N-[(4-hydroxy-2-oxo-8-(2-chlorophenyl)-2H-3-chromenyl)carbonyl]glycine
[0180] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 373, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.47 (br s, 1H), 8.10 (m, 1H), 7.77 (m, 1H), 7.67-7.50 (m, 5H), 4.14 (d, 2H, J = 6.0 Hz).
Example 18
Synthesis of N-[(4-hydroxy-2-oxo-8-(3-chlorophenyl)-2H-3-chromenyl)carbonyl]glycine
[0182] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 373, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.51 (br s, 1H), 8.06 (dd, 1H, J = 8.1, 1.5 Hz), 7.89 (m, 1H), 7.73 (s, 1H), 7.61-7.54 (m, 4H), 4.15 (d, 2H, J = 6.0 Hz).
Example 19
Synthesis of N-[(4-hydroxy-2-oxo-8-(4-chlorophenyl)-2H-3-chromenyl)carbonyl]glycine
[0184] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 373, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.49 (br s, 1H), 8.04 (dd, 1H, J = 8.1, 1.5 Hz), 7.86 (m, 1H), 7.69-7.53 (m, 5H), 4.15 (d, 2H, J = 6.0 Hz).
Example 20
Synthesis of N-[(4-hydroxy-2-oxo-8-(3-trifluoromethylphenyl)-2H-3-chromenyl)carbonyl]glycine
[0186] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 406, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.52 (br s, 1H), 8.09-7.76 (m, 6H), 7.58 (t, 1H, 7.8 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 21
Synthesis of N-[(4-hydroxy-2-oxo-8-(4-trifluoromethylphenyl)-2H-3-chromenyl)carbonyl]glycine
[0188] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 406, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.50 (br s, 1H), 8.09 (dd, 1H, 7.8, 1.5 Hz), 7.93-7.86 (m, 5H), 7.59 (t, 1H, 7.8 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 22
Synthesis of N-[(4-hydroxy-2-oxo-8-(3-trifluoromethoxyphenyl)-2H-3-chromenyl)carbonyl]glycine
[0190] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 422, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.52 (br s, 1H), 8.07 (dd, 1H, 7.8, 1.5 Hz), 7.91 (dd, 1H, 7.5, 1.5 Hz), 7.70-7.68 (m, 3H), 7.57 (t, 1H, 7.8 Hz), 7.49 (br s, 1H), 4.15 (d, 2H, J = 6.0 Hz).
Example 23
Synthesis of N-[(4-hydroxy-2-oxo-8-(4-trifluoromethoxyphenyl)-2H-3-chromenyl)carbonyl]glycine
[0192] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 422, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.50 (br s, 1H), 8.06 (dd, 1H, 8.1, 1.5 Hz), 7.89 (m, 1H), 7.78 (d, 2H, J = 8.7 Hz), 7.60-7.54 (m, 3H), 4.15 (d, 2H, J = 6.0 Hz).
Example 24
Synthesis of N-[(4-hydroxy-2-oxo-8-(3 ,4-dichlorophenyl)-2H-3-chromenyl)carbonyl]glycine
[0194] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 407, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.51 (br s, 1H), 8.06 (dd, 1H, 8.1, 1.5 Hz), 7.95-7.89 (m, 2H), 7.82 (d, 1H, J = 8.4 Hz), 7.65 (dd, 1H, J = 8.4, 1.5 Hz), 7.56 (t, 1H, J = 7.5 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 25
Synthesis of N-[(4-hydroxy-2-oxo-8-(3,4-difluorophenyl)-2H-3-chromenyl)carbonyl]glycine
[0196] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 374, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.51 (br s, 1H), 7.88 (dd, 1H, J = 7.5, 1.2 Hz), 7.82-7.75 (m, 2H), 7.68 -7.53 (m, 3H), 4.15 (d, 2H, J = 6.0 Hz).
Example 26
Synthesis of N-[(4-hydroxy-2-oxo-8-(3,4,5-trifluorophenyl)-2H-3-chromenyl)carbonyl]glycine
[0198] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 392, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.51 (br s, 1H), 8.07 (dd, 1H, J = 7.8, 1.5 Hz), 8.01-7.97 (m, 1H), 7.92 -7.89 (m, 1H), 7.71-7.66 (m, 1H), 7.63 (t, 1H, J = 7.8 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 27
Synthesis of N-[(4-hydroxy-2-oxo-8-(3-methoxyphenyl)-2H-3-chromenyl)carbonyl]glycine
[0200] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 368, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.52 (br s, 1H), 8.07 (dd, 1H, J = 7.8, 1.5 Hz), 7.87 (dd, 1H, J = 7.8, 1.5 Hz), 7.55 (t, 1H, J = 7.8 Hz), 7.45 (t, 1H, J = 7.8 Hz), 7.20-7.18 (m, 2H), 7.06-7.03 (m, 1H), 4.15 (d, 2H, J = 6.0 Hz).
Example 28
Synthesis of N-[(4-hydroxy-2-oxo-8-(4-methoxyphenyl)-2H-3-chromenyl)carbonyl]glycine
[0202] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 368, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.51 (br s, 1H), 7.98 (d, 1H, J = 7.8 Hz), 7.83-7.80 (m, 1H), 7.59-7.50 (m, 3H), 7.09 (d, 2H, J = 8.7 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 29
Synthesis of N-[(4-hydroxy-2-oxo-8-(3-methylphenyl)-2H-3-chromenyl)carbonyl]glycine
[0204] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 352, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.52 (br s, 1H), 8.03 (dd, 1H, J = 7.8, 1.5 Hz), 7.84-7.82 (m, 1H), 7.57-7.52 (m, 1H), 7.43-7.42 (m, 3H), 7.29 (br s, 1H), 4.14 (d, 2H, J = 6.0 Hz), 2.51 (t, 3H, J = 1.8 Hz).
Example 30
Synthesis of N-[(4-hydroxy-2-oxo-8-(4-methylphenyl)-2H-3-chromenyl)carbonyl]glycine
[0206] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 352, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.53 (br s, 1H), 8.02-7.99 (m, 1H), 7.84-7.82 (m, 1H), 7.57-7.51 (m, 3H), 7.36-7.33 (m, 2H), 4.14 (d, 2H, J = 6.0 Hz), 2.51 (t, 3H, J = 1.8 Hz).
Example 31
Synthesis of N-[(4-hydroxy-2-oxo-7-(6-methoxypyridin-3-yl)-2H-3-chromenyl)carbonyl]glycine
[0208] Similar procedure to Example 1 was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 369, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.54 (br s, 1H), 8.69 (d, 1H, J = 1.8 Hz), 8.21 (dd, 1H, J = 8.7, 1.8 Hz), 8.023 (d, 1H, 8.1 Hz), 7.85-7.80 (m, 2H), 6.98 (d, 1H, 8.7 Hz), 4.14 (d, 2H, J = 6.0 Hz), 2.51 (m, 3H).
Example 32
Synthesis of N-[(4-hydroxy-2-oxo-7-(pyridin-4-yl)-2H-3-chromenyl)carbonyl]glycine
[0210] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 339.
Example 33
Synthesis of N-[(4-hydroxy-2-oxo-7-(pyridin-3-yl)-2H-3 -chromenyl)carbonyl] glycine
[0212] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 339, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.55 (br s, 1H), 9.12 (s, 1H), 8.73 (s, 1H), 8.38 (d, 1H, J = 8.1 Hz), 8.11 (d, 1H, J = 8.4 Hz), 7.97 (s, 1H), 7.90 (d, 1H, J = 8.4 Hz), 7.69-7.65 (m, 1H), 4.16 (d, 2H, J = 6.0 Hz).
Example 34
Synthesis of N-[(4-hydroxy-2-oxo-7-phenoxy-2H-3-chromenyl)carbonyl]glycine
[0214] Similar procedure to the previous example was followed to arrive at the title compound, with the LC-MS [M-H]- m/z 354, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.47 (br s, 1H), 8.99 (d, 1H, 8.7 Hz), 7.55-7.49 (m, 2H), 7.33 (t, 1H, J = 7.5 Hz),7.24-7.21 (m, 2H), 7.05-7.01 (m, 1H), 6.96 (d, 1H, J = 2.4 Hz), 4.12 (d, 2H, J = 6.0 Hz).
Example 35
Synthesis of N-[(4-hydroxy-2-oxo-7-bromo-3-chromenyl)carbonyl]glycine
[0216] Synthesis was shown as of Compound 4 in Example 1, followed by similar procedure to de-protect the t-butyl group on the carboxylate group to arrive at the title compound with the LC-MS [M-H]- m/z 341, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.53 (br s, 1H), 7.93-7.86 (m, 2H), 7.68-7.65 (m, 1H), 4.14 (m, 2H).
Example 36
Synthesis of N-[(4-hydroxy-2-oxo-8-bromo-3 -chromenyl)carbonyl]glycine
[0218] Synthesis was shown as of Compound 10 in Example 16, followed by similar procedure to de-protect the t-butyl group on the carboxylate group to arrive at the title compound with the LC-MS [M-H]- m/z 341, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.51 (br s, 1H), 8.12 (d, 1H, J = 7.8 Hz), 8.00 (d, 1H, J = 7.8 Hz), 7.40 (t, 1H, J = 7.8 Hz), 4.15 (d, 2H, J = 6.0 Hz).
Example 37
Synthesis of N-[(4-hydroxy-2-oxo-6-bromo-3-chromenyl)carbonyl]glycine
[0220] Similar procedure to the previous example was followed to arrive at the title compound with the LC-MS [M-H]- m/z 341, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.56 (br s, 1H), 8.07 (d, 1H, J = 2.4 Hz), 7.99 (dd, 1H, J = 9.0, 2.4 Hz), 7.49 (d, 1H, J = 9.0 Hz), 4.14 (d, 2H, J = 6.0 Hz).
Example 38
Synthesis of N-[(4-hydroxy-2-oxo-8-(3-trifluoromethylphenyl)-2H-3-chromenyl)carbonyl]alanine
[0222] Similar procedure to Example 20 was followed, except that an alanine t-butyl ester was used instead of a glycine t-butyl ester, to arrive at the title compound, with the LC-MS [M-H]- m/z 420, and 1H-NMR (300 MHz, (CD3)2SO) δ 9.59 (br s, 1H), 8.09-8.03 (m, 2H), 7.95 (dd, 2H, J = 7.5, 1.5 Hz), 7.86-7.76 (m, 2H), 7.59 (t, 1H, 7.5 Hz), 4.57 (m, 1H), 1.48 (d, 1H, J = 7.2 Hz).
Example A. Assay of HIF-PHD2 Enzyme Activity
[0223] HIF-PHD2 activity was measured using homogeneous TR-FRET technology (see also, US2008/004817; Dao JH et al., Anal Biochem. 2009, 384:213-23). To each well of a 1/2Area 96-well plate was added 2 µL of test compound in DMSO and 40 µL of assay buffer (50 mM Tris PH7.4/0.01% Tween-20/0.1 mg/ml BSA/1 mM Sodium ascorbate/20 µg/ml Catalase/10 µM FeSO4) containing 600 nM full length PHD2. After a 30 min preincubation at room temperature, the enzymatic reactions were initiated by the addition of 8 µL of substrates(final concentrations of 0.2 µM 2-oxoglutarate and 0.5 µM HIF-1α peptide biotinyl-DLDLEMLAPYIPMDDDFQL). After 2 hr at room temperature, the reactions were terminated and signals were developed by the addition of a 50 µL quench/detection mix to a final concentration of 1 mM ortho-phenanthroline, 0.1 mM EDTA, 0.5 nM anti-(His)6LANCE reagent, 100 nM AF647-labeled Streptavidin, and 30 nM (His)6- VHL-elonginB-elonginC complex. The ratio of time resolved fluorescence signals at 665 and 620 nm was determined, and percent inhibition was calculated relative to an uninhibited control sample run in parallel.
Example B. Determination of Erythropoietin (EPO) Induction in Normal Mice
[0224] Eight-week-old male C57BL/6 mice were dosed orally with test compound at 20, 60 and 100 mg/kg. Blood samples were obtained from the orbital venous plexus 6 hours after dosing and serum was collected (see also, Robinson A, et al., Gastroenterology. 2008, 134:145-55; Hsieh MM, et al., Blood. 2007, 110:2140-7). Samples were analyzed for EPO by electrochemiluminescence-based immunoassay (MSD) according to manufacturer's instructions.
Example C. Determination of Hematology in Normal Mice
[0225] Eight-week-old male C57BL/6 mice were dosed orally with test compound at 60 mg/kg once a day for a week. Blood samples were obtained from the orbital venous plexus with time points including 1, 3 and 5 days after dosing. An Automated Hematology Analyzer MEK-6318K was used to determine hematological parameters such as erythrocyte counts (RBC), hemoglobin concentration (HGB), hematocrit value (HCT).
Example D. Pharmacokenetics Studies
[0226] Test compounds were administered in solution as a single oral dose to fasted male CD (SD) IGS rats (n=6/group) at 50 mg/kg. Plasma samples were obtained from the orbital venous plexus of each individual animal at 15', 30', 1h, 2h, 4h, 6h, 12h and 24h post-administration. Compound blood concentrations in the plasma samples were measured by HPLC.
[0227] The IC50 values for certain example compounds of invention in the Enzyme Assay of Example A are provided in Table 1 as follows.
| COMPOUND | Enzyme Assay IC50 (nM) |
| Example 1 | 250 |
| Example 2 | 150 |
| Example 3 | 150 |
| Example 4 | 150 |
| Example 5 | 150 |
| Example 6 | 150 |
| Example 7 | 150 |
| Example 8 | 150 |
| Example 9 | 150 |
| Example 10 | 150 |
| Example 11 | 150 |
| Example 12 | 150 |
| Example 13 | 150 |
| Example 14 | 300 |
| Example 15 | 150 |
| Example 16 | 350 |
| Example 17 | 200 |
| Example 18 | 90 |
| Example 19 | 150 |
| Example 20 | 100 |
| Example 21 | 90 |
| Example 22 | 100 |
| Example 23 | 150 |
| Example 24 | 30 |
| Example 25 | 150 |
| Example 26 | 150 |
| Example 27 | 150 |
| STRUCTURE | Enzyme Assay IC50 (nM) |
or a pharmaceutically acceptable salt, solvate, or chelate thereof, wherein:
n is 1 to 6;
R1 is OH, SH, NR3R4, NHC(O)R2, NHSO2R2 or sulfonyl;
R2 is H, C1-6 alkyl or substituted C1-6 alkyl;
R3 and R4 are each independently H, C1-6 alkyl, substituted C1-6 alkyl, C1-6 haloalkyl, substituted C1-6 haloalkyl; or at least one pair of R3 and R4, together with the same carbon atom to which they are attached, may join to form a 3 to 6 membered ring or a substituted 3 to 6 membered ring;
R5 is OH, SH, NH2, C1-6 alkyl, substituted C1-6 alkyl, C1-6 alkoxy, substituted C1-6 alkoxy, or sulfanyl;
each of R6 and R7 is independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, NR3R4, C(O)OH, OR12, SR12, SO2R12, CN, NO2, halo, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkylsilyl, substituted alkylsilyl, alkynylsilyl, substituted alkynylsilyl, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, or -X-R11; or R6 and R7, together with the carbon atoms to which they are attached, join to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring;
X is -N(R10)-Y- or -Y-N(R10)-;
Y is C(O), SO2, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene,
or substituted alkynylene;
R8 is H, heteroaryl, substituted heteroaryl, phenyl, or phenyl substituted by halogen,
alkyl, alkoxy, haloalkyl, or haloalkoxy wherein at least one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the
para- or meta- position; or wherein one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the
para- or meta- position; and the other of R8 and R9 is H, halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy; or wherein one of R8 and R9 is phenyl substituted with halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy at the
para- or meta- position; and the other of R8 and R9 is H;
R10 is H, C1-6 alkyl, or substituted C1-6 alkyl;
R11 is H, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl,
or substituted heteroaryl; and
R12 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl or NR3R4; wherein substituted refers to a group in which one or more hydrogen atoms are each
independently replaced with the same or different substituent(s) wherein substituents
include -X, -R33, -OH, =O, -OR33, SR33, -SH, =S, -NR33R34, =NR33, -CX3, -CF3, -CN, -NO2, -S(O)2R33,-OS(O2)OH, -OS(O)2R33, -OP(O)(OR33)(OR34), -C(O)R33, -C(S)R33, -C(O)OR33, -C(O)NR33R34, -C(O)OH, -C(S)OR33, -NR35C(O)NR33R34, -NR35C(S)NR33R34, -NR35C(NR33)NR33R34,-C(NR33)NR33R34, -S(O)2NR33R34, -NR35S(O)2R33, -NR35C(O)R33, and S(O)R33 where each X is independently a halo; each R33 and R34 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl,
substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted
heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted
heteroarylalkyl, -NR35R36, -C(O)R35 or -S(O)2R35 or optionally R33 and R34 together with the atom to which R33 and R34 are attached form one or more heterocycloalkyl, substituted heterocycloalkyl, heteroaryl,
or substituted heteroaryl rings; and R35 and R36 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl,
substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted
heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted
heteroarylalkyl, or optionally R35 and R36 together with the nitrogen atom to which R35 and R36 are attached form one or more heterocycloalkyl, substituted heterocycloalkyl, heteroaryl,
or substituted heteroaryl rings.
wherein:
R21 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy;
R22 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy;
Z1 is CR23; and R23 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy;
provided that at least one of R21 and R22 and R23, if present, is halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy.
wherein:
R21 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; and
R22 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy;
provided that at least one of R21 and R22 is halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy.
wherein:
R24 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy;
R25 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy;
Z2 is N or CR26; and R26 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy;
provided that at least one of R24 and R25 and R26, if present, is halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy.
wherein:
R24 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; and
R25 is H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy;
provided that at least one of R24 and R25 is halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy.
2-(4-hydroxy-2-oxo-7-phenyl-2H-chromene-3-carboxamido)acetic acid;
2-(7-(2-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(7-(3-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(7-(4-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(3-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(4-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(3-(trifluoromethoxy)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(4-(trifluoromethoxy)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(7-(3,4-dichlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(7-(3,4-difluorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(3,4,5-trifluorophenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-7-(3-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-7-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-m-tolyl-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-p-tolyl-2H-chromene-3-carboxamido)acetic acid;
2-(8-(2-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(8-(3-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(8-(4-chlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(3-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(4-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(3-(trifluoromethoxy)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(4-(trifluoromethoxy)phenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(8-(3,4-dichlorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(8-(3,4-difluorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-(3,4,5-trifluorophenyl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-8-(3-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-8-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-m-tolyl-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-8-p-tolyl-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-7-(6-methoxypyridin-3-yl)-2-oxo-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(pyridin-4-yl)-2H-chromene-3-carboxamido)acetic acid;
2-(4-hydroxy-2-oxo-7-(pyridin-3-yl)-2H-chromene-3-carboxamido)acetic acid; or
2-(4-hydroxy-2-oxo-8-(3-(trifluoromethyl)phenyl)-2H-chromene-3-carboxamido)acetic
oder ein pharmazeutisch annehmbares Salz, Solvat oder Chelat davon, worin:
n 1 bis 6 ist;
R1 OH, SH, NR3R4, NHC(O)R2, NHSO2R2 oder Sulfonyl ist;
R2 H, C1-6-Alkyl oder substituiertes C1-6-Alkyl is;
R3 und R4 jeweils unabhängig H, C1-6-Alkyl, substituiertes C1-6-Alkyl, C1-6-Haloalkyl, substituiertes C1-6-Haloalkyl sind, oder mindestens ein Paar von R3 und R4 kann zusammen mit dem selben Kohlenstoffatom, an das sie gebunden sind, einen 3- bis 6-gliedrigen Ring oder einen substituierten 3- bis 6-gliedrigen Ring bilden;
R5 OH, SH, NH2, C1-6-Alkyl, substituiertes C1-6-Alkyl, C1-6-Alkoxy, substituiertes C1-6-Alkoxy oder Sulfanyl ist;
jedes von R6 und R7 unabhängig H, Alkyl, substituiertes Alkyl, Alkenyl, substituiertes Alkenyl, Alkinyl, substituiertes Alkinyl, NR3R4, C(O)OH, OR12, SR12, SO2R12, CN, NO2, Halogen, Aryl, substituiertes Aryl, Heteroaryl, substituiertes Heteroaryl, Heteroarylalkyl, substituiertes Heteroarylalkyl, Heterocycloalkyl, substituiertes Heterocycloalkyl, Alkylsilyl, substituiertes Alkylsilyl, Alkinylsilyl, substituiertes Alkinylsilyl, Alkoxy, substituiertes Alkoxy, Alkoxycarbonyl, substituiertes Alkoxycarbonyl oder -X-R11 ist, oder R6 und R7 bilden zusammen mit den Kohlenstoffatomen, an die sie gebunden sind, einen 4- bis 7-gliedrigen Ring oder einen substituierten 4- bis 7-gliedrigen Ring;
X-N(R10)-Y- oder -Y-N(R10)- ist;
Y C(O), SO2, Alkylen, substituiertes Alkylen, Alkenylen, substituiertes Alkenylen, Alkinylen oder substituiertes Alkinylen ist;
R8 H, Heteroaryl, substituiertes Heteroaryl, Phenyl oder Phenyl, das mit Halogen, Alkyl, Alkoxy, Haloalkyl oder Haloalkoxy substituiert ist, ist, wobei mindestens eines von R8 und R9 Phenyl ist, das an para- oder meta-Position mit Halogen, Alkyl, Haloalkyl, Alkoxy oder Haloalkoxy substituiert ist, oder
wobei eines von R8 und R9 Phenyl ist, das an para- oder meta-Position mit Halogen, Alkyl, Haloalkyl, Alkoxy oder Haloalkoxy substituiert ist, und das andere von R8 und R9 H, Halogen, OH, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist, oder wobei eines von R8 und R9 Phenyl ist, das an para- oder meta-Position mit Halogen, Alkyl, Haloalkyl, Alkoxy oder Haloalkoxy substituiert ist, und das andere von R8 und R9 H ist;
R10 H, C1-6-Alkyl oder substituiertes C1-6-Alkyl ist;
R11 H, Heterocycloalkyl, substituiertes Heterocycloalkyl, Aryl, substituiertes Aryl, Heteroaryl oder substituiertes Heteroaryl ist; und
R12 H, Alkyl, substituiertes Alkyl, Alkenyl, substituiertes Alkenyl, Alkinyl, substituiertes Alkinyl oder NR3R4 ist, wobei substitutiert sich auf eine Gruppe bezieht, in der ein oder mehrere Wasserstoffatome jeweils unabhängig durch den gleichen oder durch unterschiedliche Substituenten ersetzt ist/sind, wobei Substituenten -X, -R33, -OH, =O, -OR33, SR33, -SH, =S, -NR33R34, =NR33, -CX3, -CF3, -CN, -NO2, -S(O)2R33, -OS(O2)OH, -OS(O)2R33, -OP(O)(OR33)(OR34),-C(O)R33, -C(S)R33, -C(O)OR33, -C(O)NR33R34, -C(O)OH, -C(S)OR33,-NR35C(O)NR33R34, -NR35C(S)NR33R34, -NR35C(NR33)NR33R34,-C(NR33)NR33R34, -S(O)2NR33R34, -NR35S(O)2R33, -NR35C(O)R33 und S(O)R33 beinhalten, wobei jedes X unabhängig Halogen ist, jedes R33 und R34 unabhängig Wasserstoff, Alkyl, substituiertes Alkyl, Aryl, substituiertes Aryl, Arylalkyl, substituiertes Arylalkyl, Cycloalkyl, substituiertes Cycloalkyl, Heterocycloalkyl, substituiertes Heterocycloalkyl, Heteroaryl, substituiertes Heteroaryl, Heteroarylalkyl, substituiertes Heteroarylalkyl, -NR35R36, -C(O)R35 oder -S(O)R35 ist oder R33 und R34 gegebenenfalls mit dem Atom, an das R33 und R34 gebunden sind, einen oder mehrere Heterocycloalkyl-, substituierte Heterocycloalkyl-, Heteroaryl- oder substituierte Heteroarylringe bilden; und
R35 und R36 unabhängig Wasserstoff, Alkyl, substituiertes Alkyl, Aryl, substituiertes Aryl, Arylalkyl, substituiertes Arylalkyl, Cycloalkyl, substituiertes Cycloalkyl, Heterocycloalkyl, substituiertes Heterocycloalkyl, Heteroaryl, substituiertes Heteroaryl, Heteroarylalkyl oder substituiertes Heteroarylalkyl sind, oder gegebenenfalls R35 und R36 zusammen mit dem Stickstoffatom, an das R35 und R36 gebunden sind, einen oder mehrere Heterocycloalkyl-, substituierte Heterocycloalkyl-, Heteroaryl- oder substituierte Heteroarylringe bilden.
worin
R21 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
R22 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
Z1 CR23 ist; und R23 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
unter der Voraussetzung, dass mindestens eines von R21 und R22 und R23, falls vorhanden, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist.
worin:
R21 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
R22 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
unter der Voraussetzung, dass mindestens eines von R21 und R22 Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist.
worin:
R24 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
R25 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
Z2 N oder CR26 ist; und R26 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
unter der Voraussetzung, dass mindestens eines von R24 und R25 und R26, falls vorhanden, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist.
worin:
R24 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist; und
R25 H, Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist;
unter der Voraussetzung, dass mindestens eines von R24 und R25 Halogen, C1-6-Alkyl, C1-6-Haloalkyl, C1-6-Alkoxy oder C1-6-Haloalkoxy ist.
2-(4-Hydroxy-2-oxo-7-phenyl-2H-chromen-3-carboxamido)essigsäure;
2-(7-(2-Chlorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(7-(3-Chlorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(7-(4-Chlorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-(3-(trifluoromethyl)phenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-(4-(trifluoromethyl)phenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-(3-(trifluoromethoxy)phenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-(4-(trifluoromethoxy)phenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(7-(3,4-Dichlorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(7-(3,4-Difluorophenyl)-4-hydroxy-2-oxo-2H-chromene-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-(3,4,5-trifluorophenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-7-(3-methoxyphenyl)-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-7-(4-methoxyphenyl)-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-m-tolyl-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-p-tolyl-2H-chromen-3-carboxamido)essigsäure;
2-(8-(2-Chlorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(8-(3-Chlorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(8-(4-Chlorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-8-(3-(trifluoromethyl)phenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-8-(4-(trifluoromethyl)phenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-8-(3-(trifluoromethoxy)phenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-8-(4-(trifluoromethoxy)phenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(8-(3,4-Dichlorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(8-(3,4-Difluorophenyl)-4-hydroxy-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-8-(3,4,5-trifluorophenyl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-8-(3-methoxyphenyl)-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-8-(4-methoxyphenyl)-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-8-m-tolyl-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-8-p-tolyl-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-7-(6-methoxypyridin-3-yl)-2-oxo-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-(pyridin-4-yl)-2H-chromen-3-carboxamido)essigsäure;
2-(4-Hydroxy-2-oxo-7-(pyridin-3-yl)-2H-chromen-3-carboxamido)essigsäure; oder
2-(4-Hydroxy-2-oxo-8-(3-(trifluoromethyl)phenyl)-2H-chromen-3-carboxamido)essigsäure
ist.
ou un sel, solvate, ou chélate pharmaceutiquement acceptable de celui-ci, dans lequel :
n est 1 à 6 ;
R1 est OH, SH, NR3R4, NHC(O)R2, NHSO2R2 ou un sulfonyle ;
R2 est H, un C1-6 alkyle ou un C1-6 alkyle substitué ;
R3 et R4 sont chacun indépendamment H, un C1-6 alkyle, un C1-6 alkyle substitué, un C1-6 haloalkyle, un C1-6 haloalkyle substitué ; ou au moins une paire de R3 et R4, avec le même atome de carbone auquel ils sont attachés, peuvent se joindre pour former un cycle de 3 à 6 chaînons ou un cycle de 3 à 6 chaînons substitué ;
R5 est OH, SH, NH2, un C1-6 alkyle, un C1-6 alkyle substitué, un C1-6 alcoxy, un C1-6 alcoxy substitué, ou un sulfanyle ;
chacun de R6 et R7 est indépendamment H, un alkyle, un alkyle substitué, un alcényle, un alcényle substitué, un alcynyle, un alcynyle substitué, NR3R4, C(O)OH, OR12, SR12, SO2R12, CN, NO2, un halo, un aryle, un aryle substitué, un hétéroaryle, un hétéroaryle substitué, un hétéroarylalkyle, un hétéroarylalkyle substitué, un hétérocycloalkyle, un hétérocycloalkyle substitué, un alkylsilyle, un alkylsilyle substitué, un alcynylsilyle, un alcynylsilyle substitué, un alcoxy, un alcoxy substitué, un alcoxycarbonyle, un alcoxycarbonyle substitué, ou -X-R11 ; ou R6 et R7, avec les atomes de carbone auxquels ils sont attachés, se joignent pour former un cycle de 4 à 7 chaînons ou un cycle de 4 à 7 chaînons substitué ;
X est -N(R10)-Y- ou -Y-N(R10)- ;
Y est C(O), SO2, un alkylène, un alkylène substitué, un alcénylène, un alcénylène substitué, un alcynylène, ou un alcynylène substitué ;
R8 est H, un hétéroaryle, un hétéroaryle substitué, un phényl, ou un phényle substitué par un halogène, un alkyle, un alcoxy, un haloalkyle, ou un haloalcoxy dans lequel au moins l'un de R8 et R9 est un phényle substitué par un halogène, un alkyle, un haloalkyle, un alcoxy, et un haloalcoxy à la position para ou méta ; ou dans lequel l'un de R8 et R9 est un phényle substitué par un halogène, un alkyle, un haloalkyle, un alcoxy, et un haloalcoxy à la position para ou méta ; et l'autre de R8 et R9 est H, un halogène, OH, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, un C1-6 haloalcoxy ; ou dans lequel l'un de R8 et R9 est un phényle substitué par un halogène, un alkyle, un haloalkyle, un alcoxy, et un haloalcoxy à la position para ou méta ; et l'autre de R8 et R9 est H ;
R10 est H, un C1-6 alkyle, ou un C1-6 alkyle substitué ;
R11 est H, un hétérocycloalkyle, un hétérocycloalkyle substitué, un aryle, un aryle substitué, un hétéroaryle, ou un hétéroaryle substitué ; et
R12 est H, un alkyle, un alkyle substitué, un alcényle, un alcényle substitué, un alcynyle, un alcynyle substitué ou NR3R4 ; dans lequel substitué fait référence à un groupe dans lequel un ou plusieurs atomes d'hydrogène sont chacun indépendamment remplacés par un ou plusieurs substituants identiques ou différents dans lequel les substituants incluent -X, -R33, -OH, =O, -OR33, SR33, -SH, =S, -NR33R34, =NR33, -CX3,-CF3, -CN, -NO2, -S(O)2R33, -OS(O2)OH, -OS(O)2R33, -OP(O)(OR33)(OR34), -C(O)R33,-C(S)R33, -C(O)OR39, -C(O)NR33R34, -C(O)OH, -C(S)OR33, -NR35C(O)NR33R34,-NR35C(S)NR33R34, -NR35C(NR33)NR33R34, -C(NR33)NR33R34, -S(O)2NR33R34,-NR35S(O)2R33, -NR35C(O)R33, et S(O)R33 où chaque X est indépendamment un halo ;
chaque R33 et R34 est indépendamment l'hydrogène, un alkyle, un alkyle substitué, un aryle, un aryle substitué, un arylalkyle, un arylalkyle substitué, un cycloalkyle, un cycloalkyle substitué, un hétérocycloalkyle, un hétérocycloalkyle substitué, un hétéroaryle, un hétéroaryle substitué, un hétéroarylalkyle, un hétéroarylalkyle substitué, -NR35R36, -C(O)R35 ou -S(O)2R35 ou facultativement R33 et R34 avec l'atome auquel R33 et R34 sont attachés forment un ou plusieurs cycles hétérocycloalkyle, hétérocycloalkyle substitués, hétéroaryle, ou hétéroaryle substitués ; et R35 et R36 sont indépendamment l'hydrogène, un alkyle, un alkyle substitué, un aryle, un aryle substitué, un arylalkyle, un arylalkyle substitué, un cycloalkyle, un cycloalkyle substitué, un hétérocycloalkyle, un hétérocycloalkyle substitué, un hétéroaryle, un hétéroaryle substitué, un hétéroarylalkyle ou un hétéroarylalkyle substitué, ou facultativement R35 et R36 avec l'atome d'azote auquel R35 et R36 sont attachés forment un ou plusieurs cycles hétérocycloalkyle, hétérocycloalkyle substitués, hétéroaryle, ou hétéroaryle substitués.
dans laquelle :
R21 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ;
R22 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ;
Z1 est CR23 ; et R23 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ;
à la condition qu'au moins l'un de R21 et R22 et R23, s'ils sont présents, soit un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy.
dans laquelle :
R21 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ; et
R22 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ;
à la condition qu'au moins l'un de R21 et R22 soit un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy.
dans laquelle :
R24 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ;
R25 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ;
Z2 est N ou CR26 ; et R26 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ;
à la condition qu'au moins l'un de R24 et R25 et R26, s'ils sont présents, soit un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy.
dans laquelle :
R24 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ; et
R25 est H, un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy ;
à la condition qu'au moins l'un de R24 et R25 soit un halogène, un C1-6 alkyle, un C1-6 haloalkyle, un C1-6 alcoxy, ou un C1-6 haloalcoxy.
l'acide 2-(4-hydroxy-2-oxo-7-phényl-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(7-(2-chlorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(7-(3-chlorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(7-(4- chlorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7-(3-(trifluorométhyl)phényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7-(4-(trifluorométhyl)phényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7-(3-(trifluorométhoxy)phényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7-(4-(trifluorométhoxy)phényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(7-(3,4-dichlorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(7-(3,4-difluorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7-(3,4,5-trifluorophényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-7-(3-méthoxyphényl)-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-7-(4-méthoxyphényl)-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7m-tolyl-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7-p-tolyl-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(8-(2-chlorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(8-(3-chlorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(8-(4-chlorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-8-(3-(trifluorométhyl)phényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-8-(4-(trifluorométhyl)phényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-8-(3-(trifluorométhoxy)phényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-8-(4-(trifluorométhoxy)phényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(8-(3,4-dichlorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(8-(3,4-difluorophényl)-4-hydroxy-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-8-(3,4,5-trifluorophényl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-8-(3-méthoxyphényl)-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-8-(4-méthoxyphényl)-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-8-m-tolyl-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-8-p-tolyl-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-7-(6-méthoxypyridin-3-yl)-2-oxo-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7-(pyridin-4-yl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-2-oxo-7-(pyridin-3-yl)-2H-chromène-3-carboxamido)acétique ;
l'acide 2-(4-hydroxy-8-(3-trifluorométhyl)phényl-2H-chromène-3-carboxamido)acétique.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description
Non-patent literature cited in the description
- SCHOFIELDRATCLIFFENature Rev. Mol. Cell Biol., 2004, vol. 5, 343-354 [0004]
- T. W. GREENEP. G. M. WUTSProtective Groups in Organic SynthesisWiley & Sons, Inc.19990000 [0137]
- DAO JH et al.Anal Biochem., 2009, vol. 384, 213-23 [0223]
- ROBINSON A et al.Gastroenterology, 2008, vol. 134, 145-55 [0224]
- HSIEH MM et al.Blood, 2007, vol. 110, 2140-7 [0224]